[Skip to Content]
[Skip to Content Landing]
Views 565
Citations 0
Editor's Note
June 3, 2019

Increasing Transparency at the US Food and Drug Administration

Author Affiliations
  • 1Editor at Large, JAMA Internal Medicine
JAMA Intern Med. 2019;179(8):1146-1147. doi:10.1001/jamainternmed.2019.1194

People who do not follow the activities of the US Food and Drug Administration (FDA) closely might be surprised to learn that the agency does not publicly disclose applications for new drugs and therapeutic biologics. The applicants may publicly disclose their applications, such as in press releases or in filings with the Securities and Exchange Commission (SEC), and usually do. The FDA, however, with limited exceptions, does not disclose any information, even about the existence of an application, until—and if—a new medical product is approved. A notable exception is when the FDA asks an advisory committee to discuss an application.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×